Literature DB >> 1329639

In vitro antibacterial activities of tosufloxacin against and uptake of tosufloxacin by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium.

J Mitsuyama1, Y Itoh, M Takahata, S Okamoto, T Yasuda.   

Abstract

The antibacterial activities of tosufloxacin and other quinolones against and apparent uptakes of tosufloxacin and other quinolones by outer membrane mutants of Escherichia coli, Proteus mirabilis, and Salmonella typhimurium were studied. The hydrophobicity of tosufloxacin was nearly equal to that of ofloxacin or lower than those of sparfloxacin and nalidixic acid. OmpF- and OmpC-deficient E. coli and 40-kDa porin-deficient P. mirabilis mutants were twofold more susceptible to tosufloxacin and sparfloxacin but two- to fourfold less susceptible to other quinolones than their parent strains. In S. typhimurium lipopolysaccharide-deficient (rough) mutants, the differences in susceptibility to tosufloxacin were similar to those to sparfloxacin and nalidixic acid. The apparent uptake of tosufloxacin by intact cells was increased in porin-deficient mutants compared with that by their parent strain. These results suggest that the permeation route of tosufloxacin across the outer membrane is different from that of other fluoroquinolones and that tosufloxacin may permeate mainly through the nonporin pathway, presumably phospholipid bilayers. However, this characteristic is independent of the hydrophobicity of the molecule.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329639      PMCID: PMC192431          DOI: 10.1128/AAC.36.9.2030

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli.

Authors:  S Nakamura; M Nakamura; T Kojima; H Yoshida
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

2.  Norfloxacin resistance in a clinical isolate of Escherichia coli.

Authors:  H Aoyama; K Sato; T Kato; K Hirai; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

3.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

4.  Interaction of the fluoroquinolone antimicrobial agents ciprofloxacin and enoxacin with liposomes.

Authors:  J Bedard; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

5.  Cross-resistance to nalidixic acid, trimethoprim, and chloramphenicol associated with alterations in outer membrane proteins of Klebsiella, Enterobacter, and Serratia.

Authors:  L Gutmann; R Williamson; N Moreau; M D Kitzis; E Collatz; J F Acar; F W Goldstein
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

6.  Isolation of outer membrane proteins of Escherchia coli and their characterization on polyacrylamide gel.

Authors:  J Uemura; S Mizushima
Journal:  Biochim Biophys Acta       Date:  1975-12-01

7.  Contribution of permeability and sensitivity to inhibition of DNA synthesis in determining susceptibilities of Escherichia coli, Pseudomonas aeruginosa, and Alcaligenes faecalis to ciprofloxacin.

Authors:  J Bedard; S Chamberland; S Wong; T Schollaardt; L E Bryan
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

8.  Quinolone-resistant mutations of the gyrA gene of Escherichia coli.

Authors:  H Yoshida; T Kojima; J Yamagishi; S Nakamura
Journal:  Mol Gen Genet       Date:  1988-01

9.  Outer membrane permeation of beta-lactam antibiotics in Escherichia coli, Proteus mirabilis, and Enterobacter cloacae.

Authors:  T Sawai; R Hiruma; N Kawana; M Kaneko; F Taniyasu; A Inami
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

10.  Mechanisms of quinolone resistance in Escherichia coli: characterization of nfxB and cfxB, two mutant resistance loci decreasing norfloxacin accumulation.

Authors:  D C Hooper; J S Wolfson; K S Souza; E Y Ng; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

View more
  7 in total

Review 1.  The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.

Authors:  Xian-Zhi Li; Patrick Plésiat; Hiroshi Nikaido
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

2.  Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar typhimurium.

Authors:  E Giraud; A Cloeckaert; D Kerboeuf; E Chaslus-Dancla
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 3.  Plasmid-mediated quinolone resistance in Enterobacteriaceae: a systematic review with a focus on Mediterranean countries.

Authors:  B Yanat; J-M Rodríguez-Martínez; A Touati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-11-26       Impact factor: 3.267

4.  Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.

Authors:  P Heisig; R Tschorny
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

5.  Trovafloxacin is active against Toxoplasma gondii.

Authors:  A A Khan; T Slifer; F G Araujo; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

6.  Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones.

Authors:  R A Zabinski; K J Walker; A J Larsson; J A Moody; G W Kaatz; J C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

7.  Bacteremia due to fluoroquinolone-resistant Escherichia coli in two immunocompromised patients.

Authors:  W V Kern; A Markus; E Andriof
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-02       Impact factor: 3.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.